Suchergebnisse - "Rizvi, Hira"

PubPharm (6)

1

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Alessi, J. | Wang, X. | Elkrief, A. | +32

2

Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Huicochea Castellanos, S. | Pagano, A. | Plodkowski, A. | +8

3

Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Mezquita, L. | Preeshagul, I. | Auclin, E. | +34

4

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status

enthalten in: Journal for immunotherapy of cancer | 2020

von Alessi, J. | Ricciuti, B. | Jiménez-Aguilar, E. | +12

5

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Tio, M. | Rai, R. | Ezeoke, O. | +22

6

Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors

enthalten in: Gynecologic oncology reports | 2018

von Martin, M. | Sabari, J. | Turashvili, G. | +4

1
[1]